A new research survey of 500 biopharma executives, commissioned by TetraScience and AWS, reveals why life sciences companies need to rethink their data platforms.
Replatforming scientific data to an open cloud platform while transforming the data to FAIR (Findable, Accessible, Interoperable, Reusable) principles significantly impacts three key industry drivers:
o Speed: Learning from experiments faster, reducing time to market for final molecules.
o Cost: Improving productivity, increasing operational efficiency, increasing return on investment (ROI).
o Risk: Improving safety, reducing errors, improving compliance with regulatory requirements